Search

A 22-year-old woman presented with new-onset palpitation and dyspnea. Cardiovascular examination revealed continuous murmur at the left upper parasternal area. Echocardiographic evaluation revealed a connection from the aorta, tunneling up to the intra-atrial septum, which made a giant aneurysmal

A 74-year-old man with progressive breathlessness was diagnosed as having heart failure due to patent ductus arteriosus (PDA) ([Figure 1][1]). Percutaneous PDA closure was performed transvenously using a 16-mm Amplatzer Vascular Plug II (St. Jude Medical, St. Paul, Minnesota). His blood pressure

Significant residual mitral regurgitation (MR) may persist after MitraClip (Abbott Vascular, Santa Clara, California) implantation in up to 7% of patients with degenerative MR [(1)][1]. Treatment of the residual MR with an adjacent MitraClip may not be feasible, because of commissural location

MitraClip therapy is a well-established transcatheter treatment for patients with symptomatic mitral regurgitation (MR) and high surgical risk. To date, more than 30,000 patients have been treated worldwide. Restoring coaptation between the anterior and posterior mitral leaflets with satisfactory

A 15-year-old post-neonatal repair of truncus arteriosus sustained an anterior leaflet mitral valve injury during elective aortic root replacement and aortic valve repair, resulting in severe mitral regurgitation ([Figure 1][1], [Online Video 1][2]). He was deemed not to be a surgical candidate in

A 67-year-old man with scleroderma was diagnosed with a giant (12.1 × 8.2 × 7.9 cm) saphenous vein graft (SVG) aneurysm while undergoing evaluation for dyspnea 15 years post-coronary artery bypass surgery. Computed tomography demonstrated the aneurysm to arise from the SVG supplying the second

A 75-year-old man presented with worsening right heart failure on the background of previous supracoronary ascending aortic replacement and bioprosthetic aortic valve replacement for bicuspid aortopathy. Transthoracic echocardiography demonstrated continuous flow on color Doppler from an ascending

Several publications report strokes early after embolotherapy for pulmonary arteriovenous malformations (pAVM) ([1–3][1]). Various mechanisms are discussed for this event, including embolization of newly formed thrombotic material originating from the aneurysmal sac after occlusion of the arterial

ObjectivesThis study sought to evaluate acute and long-term outcomes of percutaneous paravalvular regurgitation (PVR) closure after transcatheter aortic valve replacement (TAVR).BackgroundSevere symptomatic PVR is a predictor of all-cause mortality after TAVR. The current use of devices for transcatheter closure of PVR has been adapted from other indications without known long-term outcomes.MethodsThe study population consisted of a series of cases pooled together from an international multicenter experience. Patients underwent transcatheter implantation of a closure device for the treatment of clinically relevant PVR after TAVR with balloon-expandable or self-expandable prostheses. Procedural success was defined by successful deployment of a device with immediate reduction of PVR to a final grade ≤2 as assessed by echocardiography.ResultsTwenty-seven procedures were performed in 24 patients with clinically relevant PVR after the index TAVR procedure (54.2% Edwards Sapien [Edwards Lifesciences, Irvine, California], 45.8% CoreValve [Medtronic, Minneapolis, Minnesota]). The study population included 75% men with a mean age of 80.6 ± 7.1 years and mean Society of Thoracic Surgeon score of 6.6%. The most frequently used device was Amplatzer Vascular Plug (St. Jude Medical, St. Paul, Minnesota) in 80% of the cases. Overall, 88.9% (24 of 27) of the procedures were technically successful and the results assessed by echocardiography were durable. However, cumulative survival rates at 1, 6, and 12 months were 83.3%, 66.7%, and 61.5%. Most of the deaths (8 of 11) were due to noncardiac causes.ConclusionsTranscatheter closure of PVR after TAVR can be performed with a high procedural success rate; however, the long-term mortality remains high mainly due to noncardiac causes.